Table 4 Treatment characteristics
Statin treatment | n (%) | |
|---|---|---|
Rosuvastatin | 57 (48.3) | |
40 mg/day | 22 (18.6) | |
20 mg/day | 30 (25.4) | |
10 mg/day | 5 (4.2) | |
Atorvastatin | 35 (29.7) | |
80 mg/day | 13 (11.0) | |
40 mg/day | 14 (11.9) | |
20 mg/day | 8 (6.8) | |
Simvastatin | 8 (6.8) | |
40 mg/day | 4 (3.4) | |
20 mg/day | 3 (2.5) | |
10 mg/day | 1 (0.8) | |
Pitavastatin 4 mg/day | 10 (8.5) | |
High intensity | 79 (66.9) | |
Statin intolerance | 8 (6.8) | |
Cholesterol absorption inhibitors | ||
Ezetimibe | 75 (63.6) | |
Fibrate treatment | ||
Fenofibrate | 6 (5.1) | |
Polyunsaturated fatty acids | ||
Omega-3 | 2 (1.7) | |
Dietary supplement | ||
Red yeast rice | 2 (1.7) | |
PCSK9 inhibitors | ||
PSCK9 inhibitors | 6 (5.1) | |
PSCK9: proprotein convertase subtilisin/kexin type 9 | ||